iiinova — where your digital self keeps evolving

Simmaron Research Foundation @simmaronresearch.bsky.social · 21/09/2026

We are proud to announce that we have achieved an R-01 grant from NIH. This prestigious award is a huge feat for ME research and highlights the work that Simmaron has been doing to uncover mechanistic drivers in #ME and #LongCovid that can lead to treatment options for patients. Congrats team!

052

Simmaron Research Foundation @simmaronresearch.bsky.social · 21/09/2026

Our rapamycin studies are very promising, yet we know the findings need to be confirmed in a placebo-controlled trial. Listen to Dr. Gunnar Gottschalk explain why we studied mechanisms of rapamycin in responders, and how a random controlled trial can cut through heterogeneity in #ME. #PEM #Longcovid

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 12/09/2026

The recently published findings from Phase II of our rapamycin treatment trial describe 3 pathways that are disrupted in #ME patients and are improved through treatment with Rapamycin. We summarize those findings in a series of updates, starting with mitochondrial dysfunction. bit.ly/4xhafmi

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 08/09/2026

Interested in finding out more about our #ME and #LongCovid research and upcoming work? Sign up for email updates! www.simmaronresearch.com/signup #MECFS #POTS

033

Simmaron Research Foundation @simmaronresearch.bsky.social · 29/08/2026

Dr. Avik Roy summarizes our first scientific aim with Phase II of the rapamycin trial. Take a listen for yourself and find out why this trial is different from past endeavours.

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 29/08/2026

Does Rapamycin improve mitochondrial energy metabolism in ME/CFS patients? Listen to Dr. Avik Roy explain the importance of mitochondrial energy and the impact found in the Rapamycin trial.

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 09/08/2026

Our decentralized #rapamycin trial allowed #SevereME patients to participate. When necessary, we reduced blood draw volumes and made every effort to help patients complete surveys. In a few cases, this meant conducting surveys over the phone. We all need new models. #ME #MECFS #Longcovid

030

Simmaron Research Foundation @simmaronresearch.bsky.social · 23/07/2026

A Simmaron short explaining how our #rapamycin observational trial is filling unmet needs in #MECFS treatment trials. @ggottschalk.bsky.social @avikroy.bsky.social @AgelessRX #POTS #Longcovid

062

Simmaron Research Foundation @simmaronresearch.bsky.social · 18/07/2026

Here's a short summary of our newest Jnl of Translational Medicine pub sharing results of Ph 2 of our rapamycin trial & showing how rapamycin may tie three converging threads of metabolic impairment together in #MECFS. #Longcovid #POTS simmaronresearch.salsalabs.org/jtrrapaph2pub

0124

Simmaron Research Foundation @simmaronresearch.bsky.social · 16/07/2026

Rapamycin may tie three converging threads of metabolic impairment together in #MECFS. Here's a replay of Simmaron's team detailing new findings from Ph 2 of our rapamycin trial, in case you missed it! TY Solve for hosting us! #LongCovid #POTS www.youtube.com/watch?v=oJnU...

085

Simmaron Research Foundation @simmaronresearch.bsky.social · 14/07/2026

2 hours to go! Register and hear our team detail findings published yesterday in Journal of Translational Medicine on Ph II of our rapamycin trial.

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 13/07/2026

We're excited to announce Journal of Translation Medicine published findings from Phase II of our clinical trial evaluating low-dose rapamycin in people with #MECFS. This work builds upon years of laboratory research into mTOR signaling, autophagy, and mitochondrial dysfunction. 🧵

153

Simmaron Research Foundation @simmaronresearch.bsky.social · 03/07/2026

@solveme.bsky.social Our Simmaron science team has upcoming news you want to hear! Sign up for updates, and help keep us out of your spam folder. #ME #MECFS #LongCovid #PEM www.simmaronresearch.com/signup

072

Reposted by Simmaron Research Foundation

Solve M.E. @solveme.bsky.social · 30/06/2026

Register today for our free webinar, “Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS,” with the Simmaron Research team. Tues. July 14, @ 3:00 pm PT / 6:00 pm ET. ow.ly/jsrZ50Zg3CA

Virtual panel announcement for a July 14 webinar on repurposing rapamycin for ME/CFS featuring four experts from Simmaron Research and Solve M.E. President & CEO Emily Taylor.

093

Simmaron Research Foundation @simmaronresearch.bsky.social · 25/06/2026

What if a single gene involved in cellular recycling could help explain symptoms of #MECFS and #LongCOVID? Our findings published in Inflammation Research this Spring dig into that question. This study focused on ATG13, a key regulator of autophagy, which we found increased in a subset of patients.

Chart explaining the loss of autophagy through mitochondria dysfunction, inflammatory microphages known as M1, and Myelin damage that leads to Muscle Impairment and Nerve Dysfunction.

160

Simmaron Research Foundation @simmaronresearch.bsky.social · 21/04/2026

Why placebo trials for #MECFS & #LongCovid? It’s how drugs get approved, and we have none. Placebo trials change medicine. We'll compare RAPAMYCIN with placebo, and all will receive treatment. We seek to prove which subset responds and change medicine, finally. www.simmaronresearch.com/donate

010

Reposted by Simmaron Research Foundation

Solve M.E. @solveme.bsky.social · 15/04/2026

Watch! Dr. Avik Roy & Dr. Gunnar Gottschalk of Simmaron Research Foundation share how six years of work on the molecular mechanisms of #MECFS has led to one of the only ongoing clinical trials specifically designed around a defined biological target. youtu.be/OMmjcTKxivU #MEAwarenessHour

Banner for ME/CFS Q&A series featuring a compass on wood and researchers Dr. Gunnar Gottschalk and Dr. Avik Roy from Simmaron Research Institute.

121

Simmaron Research Foundation @simmaronresearch.bsky.social · 04/04/2026

#ME & #LongCovid have no FDA approval, no successful placebo-controlled trial, no accepted biomarker. Our placebo-controlled rapamycin trial is a strategic opportunity for change. Read how testing biomarkers with treatment holds so much promise: simmaronresearch.salsalabs.org/placebotrial #MECFS

010

Simmaron Research Foundation @simmaronresearch.bsky.social · 02/04/2026

Why low-dose rapamycin? It regulates mTOR & autophagy, pathways that may be disrupted in #MECFS & #LongCOVID. Our placebo-controlled trial measures biomarkers, immune signaling, and metabolics to learn why some improve, and who is likely to. Help us prove it. DONATE: www.simmaronresearch.com/donate

153

Simmaron Research Foundation @simmaronresearch.bsky.social · 29/03/2026

Our placebo-controlled trial will pay for the costs of rapamycin, placebo, safety tests, biomarker tests and clinical work, to ease patient burden & so results aren’t influenced by costs. A generous donor will double your gift! Help prove treatments for #ME #LongCovid www.simmaronresearch.com/donate

030

Simmaron Research Foundation @simmaronresearch.bsky.social · 25/03/2026

1️⃣ #MECFS and #LongCOVID affect millions worldwide — yet no @FDA approved treatment exists. 2️⃣ Our team at Simmaron Research is studying low-dose rapamycin, a drug that regulates cellular pathways involved in inflammation and autophagy. Thread 🧵1/4

141

Simmaron Research Foundation @simmaronresearch.bsky.social · 21/03/2026

We’re launching a placebo-controlled study of rapamycin for #MECFS and #LongCOVID. Early data from our Phase II trial shows promise — now we must test it under rigorous blinded conditions. Help us make it happen. Donate to support the study. www.simmaronresearch.com/donate #ME #Rapamycin

02611